Status:
COMPLETED
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral anti...
Eligibility Criteria
Inclusion
- After the participating physician's decision has been made to initiate once-daily Levemir® therapy, any patient with Type 2 diabetes who is currently treated with diet, exercise and one or more OADs can be offered to participate
Exclusion
- Current treatment with insulin
- Known or suspected allergy to Levemir® or excipients
- Children below the age of 6 years
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant within the next 6 months or are not using adequate contraceptive methods (contraceptive measures as required by local law or practice)
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
18481 Patients enrolled
Trial Details
Trial ID
NCT00825643
Start Date
April 1 2008
End Date
March 1 2011
Last Update
February 13 2017
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mississauga, Canada, L4W 4XI
2
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100004
3
Novo Nordisk Investigational Site
Mainz, Germany, 55127
4
Novo Nordisk Investigational Site
Kfar Saba, Israel, 44425